Proteolix raises $79M for cancer treatment
Proteolix, which is developing drugs to treat cancer by disrupting key cell functions, has raised $79 million in a third round of funding, according to VentureWire. That’s the third largest biotech funding this year.
Nomura Phase4 Ventures, a new investor, led the round, with participation from new backer Westfield Capital Management and existing investors Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, U.S. Venture Partners and Vertical Group.
The new funding should allow South San Francisco-based Proteolix to conduct Phase II and Phase III clincial trials of its lead drug, Carfilzomib.
Next Story: TC50: Webvanta hopes to cut the costs of creating an information portal
Previous Story: DEMOfall 08: TravelMuse plans to simplify social travel planning
About the Author, Anthony Ha
Anthony is a senior editor at VentureBeat, as well as its reporter on media, advertising, and social networks. Before joining the site in 2008, Anthony worked at the Hollister Free Lance, where he won awards from the California Newspaper Publishers Association for breaking news coverage and writing. He attended Stanford University and now lives in San Francisco. Reach him at anthony@venturebeat.com. (All story pitches should also be sent to tips@venturebeat.com) You can also follow Anthony on Twitter.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
